interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Delafloxacin Meglumine

Generic competition · all medicines · read 12 November 2026

Is there a generic of Delafloxacin Meglumine, and who makes it?

Delafloxacin Meglumine appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Delafloxacin Meglumine2 dosage-form groups in the Orange Book
0generic makers listed
  1. Delafloxacin Meglumine appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Powder, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Baxdela. No generic is listed as marketed.

2015202020252030203501brand 2017data datePatent 9200088 listed to expire 13 March 2029Patent 9750822 listed to expire 13 March 2029Patent 7635773 listed to expire 13 March 2029Patent 8410077 listed to expire 13 March 2029Patent 8871938 listed to expire 23 September 2029Patent RE46617 listed to expire 28 December 2029Patent 7728143 listed to expire 19 June 2031Patent 12138257 listed to expire 1 May 2032Patent 9493582 listed to expire 27 February 2033Patent 12558349 listed to expire 14 March 2034Patent 12036219 listed to expire 2 June 2034Exclusivity GAIN to 19 June 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 19 June 2027Exclusivity GAIN Baxdela
  • 13 March 2029Patent 9200088 drug product
  • 13 March 2029Patent 9750822 drug product
  • 13 March 2029Patent 7635773 drug product
  • 13 March 2029Patent 8410077 drug product
  • 23 September 2029Patent 8871938 drug substance
  • 28 December 2029Patent RE46617 drug substance
  • 19 June 2031Patent 7728143 drug substance
  • 1 May 2032Patent 12138257 drug product

3 more patents are listed.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Baxdela. No generic is listed as marketed.

2015202020252030203501brand 2017data datePatent 8871938 listed to expire 23 September 2029Patent RE46617 listed to expire 28 December 2029Patent 7728143 listed to expire 19 June 2031Exclusivity GAIN to 19 June 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 19 June 2027Exclusivity GAIN Baxdela
  • 23 September 2029Patent 8871938 drug substance
  • 28 December 2029Patent RE46617 drug substance
  • 19 June 2031Patent 7728143 drug substance

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.